Accumulating data indicate that METTL14 as a m6A “writer” shows a decreased expression in CRC [7, 26], bladder cancer [8] and breast cancer [9], but an increased level in thyroid and pancreatic cancers [10, 11]. This evidence concerns the gene METTL14 and familial pancreatic carcinoma.